Overview
Overview
Articular chondrocytes differentiated from UCT-WJ-MSCs; producing type II collagen and aggrecan for cartilage matrix regeneration and joint repair
FOR RESEARCH USE AND INTERNATIONAL USE ONLY
| Source & Manufacturing |
|---|
| Derived from P2 UCT-WJ-MSCs via chondrogenic pellet culture |
| TGF-β3 BMP-6 dexamethasone in serum-free chondrogenic medium |
| DMSO-free cryopreservation |
| Post-thaw viability 95% |
| Markers: Type II Collagen⁺, Aggrecan⁺, SOX9⁺, COL2A1⁺, CD44⁺ |
| Alcian Blue staining confirms sulfated proteoglycan production prior to release. |
Clinical Overview
Clinical Overview
Articular cartilage has minimal intrinsic healing capacity due to avascularity and limited progenitor cell content. Akira Chondrocytes derived from UCT-WJ-MSCs exhibit enhanced proliferative and matrix-producing capacity compared to adult chondrocytes, with lower dedifferentiation risk under in vitro expansion. These cells restore cartilage matrix integrity through both direct ECM deposition and paracrine modulation of joint inflammation. Delivered intra-articularly (with or without scaffold), they engage host chondrocytes via exosomal miRNAs (SOX9, miR-140) that suppress catabolism and promote anabolism. A 2024 systematic review of WJ-MSC clinical trials specifically for KOA (n=97 patients, 6 studies) confirmed significant functional improvement with no serious adverse events — providing the best available clinical evidence for this cell class.[1]
Process
Mechanism of Action
Direct ECM Production: SOX9+ chondrocytes synthesize type II collagen fibrils and aggrecan proteoglycans — the primary structural components of articular cartilage. This matrix deposition restores mechanical load-bearing and joint lubrication function.
Inflammation Suppression: MMP expression (MMP-13, MMP-3, ADAMTS-5) in the joint space is reduced via IL-10 and TGF-β secretion and miR-140 transfer in exosomes — slowing cartilage catabolism in osteoarthritis.
Anabolic Signaling: IGF-1 and FGF-2 secreted by Akira Chondrocytes activate chondrocyte proliferation pathways and upregulate collagen II and aggrecan gene expression in neighboring host cartilage.
Scaffold Compatibility: Akira Chondrocytes adhere to hyaluronic acid, fibrin, collagen, and bioprinted scaffolds, enabling cartilage tissue engineering constructs for focal defect repair, meniscal augmentation, and intervertebral disc applications.
Post-Thaw Superior Performance: UCT-derived chondrocytes demonstrate 40% greater GAG (glycosaminoglycan) production per cell vs adult-source chondrocytes after equivalent expansion — reflecting the youthful, high-potency donor origin.
Biomarkers
Key Biomarkers & Molecular Cargo
| Marker / Molecule | Functional Role |
|---|---|
| SOX9 | Master chondrogenic transcription factor; drives COL2A1, ACAN expression |
| Type II Collagen (COL2A1) | Primary structural cartilage protein; tensile strength and matrix integrity |
| Aggrecan (ACAN) | Sulfated proteoglycan; compressive load bearing, water retention |
| miR-140 | Cartilage-specific miRNA; suppresses MMP-13, ADAMTS-5 catabolism |
| TGF-β3 / IGF-1 | Anabolic growth factors for matrix production and chondrocyte survival |
| CD44 | Hyaluronate receptor; mediates chondrocyte adhesion to ECM and scaffold |
| IL-10 / IL-1Ra | Anti-inflammatory cytokines suppressing synovial inflammation in OA |
Applications
Therapeutic Applications
- Knee Osteoarthritis (Grades I–IV) — intra-articular injection, chondrogenic regeneration
- Focal Articular Cartilage Defects — autologous chondrocyte implantation analogue
- Rheumatoid Arthritis Joint Damage — matrix restoration immunomodulation
- Intervertebral Disc Degeneration — nucleus pulposus regeneration (disc scaffold)
- Meniscal Tears & Degeneration — meniscal fibrocartilage repair
- Patellofemoral Chondromalacia — patellar cartilage restoration
- Sports-related Cartilage Injuries — focal defect repair for athletes
- Post-traumatic Articular Damage — post-fracture cartilage healing
Evidence
Clinical & Preclinical Evidence
The 2024 systematic review of WJ-MSC intra-articular injections for KOA (n=97 patients, 134 knees, 6 studies, follow-up 3–48 months) showed statistically significant improvements in VAS pain (mean reduction 3.2 points), WOMAC total score, KOOS, and IKDC — with no serious adverse events across all studies. Multiple-injection protocols produced superior outcomes over single injections.[1]
A 2023 systematic review and meta-analysis (Frontiers in Endocrinology) of MSC therapies for OA across multiple RCTs confirmed consistent pain relief and functional improvement, with early MRI evidence of cartilage volume preservation in treated joints. The review endorsed allogeneic UCT-derived MSCs as among the best-characterized sources for joint therapy.[2]
CARTISTEM® (hUCB-MSC product) Phase III pivotal trial using umbilical cord blood-derived MSCs in knee cartilage defects is underway, targeting superiority over surgical debridement at 2-year follow-up — establishing regulatory precedent for UCT-derived chondrocyte-lineage therapy.[3]
In preclinical models of full-thickness cartilage defects, UCT-MSC-derived chondrocytes delivered in fibrin glue resulted in histological scores (ICRS score) of 8.4/12 at 12 weeks vs 3.1/12 in untreated defects — demonstrating substantial but not yet complete regeneration consistent with early-stage repair. COL2A1 expression was 85% of normal articular cartilage by immunohistochemistry.
A Phase II RCT of allogeneic adipose-MSC intra-articular injection confirmed cartilage regeneration on MRI with reduction of IL-1β and TNF-α in synovial fluid — mechanistically mirroring the expected outcome of Akira Chondrocyte delivery.[4]